Llwytho...
Constraints on the Dominant Mechanism for HIV Viral Dynamics in Patients on Raltegravir
BACKGROUND: Raltegravir is the first publicly released HIV-1 integrase inhibitor. In clinical trials, patients on a raltegravir-based HAART regimen were observed to have 70% less viremia in the second phase-decay of viremia than patients on an efavirenz-based HAART regimen. Because of this accelerat...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2009
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2980788/ https://ncbi.nlm.nih.gov/pubmed/19430101 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|